BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Read more
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster

Trending Articles

  1. Orion secures exclusive license to Abzena’s CHAb-designed oncology antibody The deal strengthens Orion’s cancer R&D pipeline with a de-risked monoclonal antibody developed using Abzena’s proprietary Composite Human Antibody (CHAb) and AbZelectPRO platforms
  2. Aenova expands sterile fill & finish manufacturing at its Latina site New line to boost biologics capacity and support a wide range of container formats
  3. GemPharmatech and MSK to enter antibody research collaboration The Memorial Sloan Kettering Cancer Center (MSK) will use GemPharmatech's antibody discovery platform to accelerate the development of next-generation cancer therapies
  4. Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
  5. Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation

You may also like

Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Research & Development

Immunology CRO reports shift to autoimmunity projects

RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
Research & Development

Merck partners with Promega to advance 3D cell drug discovery technologies

Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Subscribe now